In late 2013 and early 2014, 2 studies reported increased myocardial infarction and stroke associated with testosterone use. 3 , 4 The US Food and Drug Administration (FDA) issued a safety bulletin on January 31, 2014. We assessed recent trends in testosterone prescribing.
Methods | We used data from Clinformatics Data Mart (CDM), one of the nation's largest commercial health insurance databases with more than 18 000 000 enrollees. Persons in the south and those aged 21 to 64 years are overrepresented in the data set. Separate cohorts were identified each year from 2002 through 2016, consisting of men 30 years and older with continuous enrollment during the index and prior year. For each year, we reported the percentage of men who were prescribed testosterone therapy and new testosterone users (no use in the prior year). We examined use over time with an interrupted time series analysis using joinpoint regression. Because testosterone use differs by age and region, 1,2 we stratified by these factors. All analyses were performed using SAS (SAS Institute), version 9.4, and the Joinpoint Regression Program (National Cancer Institute), version 4.5.0. This study has limitations. First, commercial insurance data selected for employed males; the results for men 65 years and older are not generalizable to most older men who are retired and on Medicare. Second, men may obtain testosterone from clinicians not reimbursed by their insurance. Third, indications for testosterone use could not be determined. Fourth, the demographic composition of the CDM population changed over time. Fifth, the reasons for the decrease in testosterone prescriptions cannot be determined. A recent study within the Veterans Administration system reported a 40% decrease in testosterone prescriptions from 2013 to 2016.
5 Given the debate that has surrounded this issue, 6 continued monitoring of testosterone prescribing trends will be important.
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